Talisman uses novel, proprietary human stem cell models of neurodegenerative disease. This enables rapid and relevant target identification and validation, as well as testing of candidate therapeutics. This approach significantly accelerates drug discovery.
Our technology transforms the discovery of new disease-modifying treatments by avoiding the limitations of current neurological drug discovery approaches. Human stem cells are used to produce disease-relevant neurons and glial cells that replicate the different aspects of neureodegenerative disease , offering several different phases of the disease to target therapeutically. By using human stem cell-based models early in the drug discovery process, we identify compounds that have much greater relevance to the disease process in the part of the human brain affected by the disease.